World journal of clinical cases · 2025
Unexpected thrombocytopenia of a rare tamoxifen-induced complication in breast cancer therapy: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Swamy Anusha Mruthyunjaya, Sehrawat Amit, Sundriyal Deepak
Аннотация
BACKGROUND: Tamoxifen, a selective estrogen receptor modulator, is pivotal in managing hormone receptor-positive breast cancer. While its common side effects are well-documented, tamoxifen-induced thrombocytopenia is a rare, serious adverse event requiring drug discontinuation.
CASE SUMMARY: We report a case of tamoxifen-induced thrombocytopenia in a 51-year-old premenopausal woman with breast cancer, occurring within 4 weeks of initiating adjuvant tamoxifen therapy. Platelet counts normalized after drug cessation, but thrombocytopenia recurred upon rechallenge, leading to permanent discontinuation.
CONCLUSION: This case underscores the need for regular complete blood count monitoring in patients on tamoxifen to detect rare hematologic adverse events promptly.
CASE SUMMARY: We report a case of tamoxifen-induced thrombocytopenia in a 51-year-old premenopausal woman with breast cancer, occurring within 4 weeks of initiating adjuvant tamoxifen therapy. Platelet counts normalized after drug cessation, but thrombocytopenia recurred upon rechallenge, leading to permanent discontinuation.
CONCLUSION: This case underscores the need for regular complete blood count monitoring in patients on tamoxifen to detect rare hematologic adverse events promptly.